Pramiracetam: Overview of Uses and Effects

1. Studied Conditions

Pramiracetam has been studied for various conditions, including:

• Cognitive impairment
• Memory disorders
• Alzheimer's disease
• Dementia
• Attention disorders

2. Efficacy in Treating Conditions

While some studies suggest that pramiracetam may improve memory and cognitive function in certain individuals, the evidence is not conclusive. The efficacy of pramiracetam in treating the aforementioned conditions varies and requires further research to confirm its therapeutic potential.

3. Health Benefits

Potential health benefits associated with pramiracetam include:

• Enhanced memory and learning capacity
• Improved cognitive functions
• Neuroprotective effects

4. Downsides

Despite its potential benefits, pramiracetam can have downsides, such as:

• Headaches
• Gastrointestinal discomfort
• Dizziness
• Insomnia or sleep disturbances
• Anxiety or agitation

It is important to note that pramiracetam is not approved by the FDA for medical use and should be used with caution.

5. Genetic Variations and Effects

Currently, there is limited research on the interaction between pramiracetam and specific genetic variations. As such, it is unclear whether pramiracetam is particularly beneficial or harmful for individuals with certain genetic profiles. Personalized medical advice and genetic counseling are recommended for those considering pramiracetam use.

Pramiracetam Research Summary

Introduction

Pramiracetam is a nootropic drug with the chemical formula C₁₄H₂₈N₃O₂⁺·HSO₄^-, studied for its potential to enhance cognitive functions. It features a pyrrolidine ring in an envelope conformation and is part of a group of compounds known as N-[(dialkylamino)alkyl]-2-oxo-1-pyrrolidineacetamides. Pramiracetam is being investigated for its effects on spatial learning and memory, with promising results in animal studies and human trials, including those with primary degenerative dementia such as Alzheimer's disease.

Effects on Learning and Memory

Research on rats has shown that pramiracetam significantly improves long-term memory in tasks like navigating a radial arm maze without affecting short-term memory. In mice, compounds related to pramiracetam reversed memory loss caused by electroconvulsive shock, indicating potential benefits for cognitive deficits.

Pharmacokinetics

Studies on pramiracetam's pharmacokinetics reveal that peak plasma concentrations are reached 2-3 hours after administration, with a half-life ranging from 4.5 to 6.5 hours. It is distributed widely in the body, with high concentrations in the kidneys, liver, and brain, and is excreted primarily through urine and feces. Pramiracetam has demonstrated safety in animal studies and is well-tolerated in humans.

Clinical Use and Mechanism of Action

As part of a subgroup of nootropic drugs, pramiracetam shows promise for treating cognitive deficits from brain injuries. It might affect glutamate receptors, and its derivatives have varying clinical efficacy and mechanisms of action. Pramiracetam has been found to be more effective than other compounds like piracetam in normalizing EEG patterns of aged rats, suggesting a role in improving cognitive function.

Research Findings

• Pramiracetam has been shown to improve memory retention and enhance recognition memory in animal studies.
• It has a specific therapeutic window, observable across behavioral, electroencephalographic, and cellular levels.
• Pramiracetam and related compounds may affect cholinergic neuronal activity, influencing hippocampal choline uptake.
• It counteracts memory impairment induced by scopolamine in healthy volunteers, suggesting potential for amnesia treatment.

Conclusion

While pramiracetam has shown effectiveness in preclinical studies and some human trials, results in Alzheimer's disease patients have been mixed, with limited symptomatic benefit. Ongoing research aims to better understand its mechanism of action and potential therapeutic uses.

References:

1. Diisoprop-yl{2-[2-(2-oxopyrrolidin-1-yl)acetamido]eth-yl}ammonium hydrogen sulfate
2. The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task
3. Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam
4. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders
5. Pharmacokinetics of oral pramiracetam in normal volunteers
6. Pharmacokinetics of pramiracetam in healthy volunteers after oral administration
7. [Pharmacokinetics of pramiracetam in animals]
8. Clinical pharmacokinetics of drugs for Alzheimer's disease
9. Selective effects of aniracetam across receptor types and forms of synaptic facilitation in hippocampus
10. Involvement of a steroidal component in the mechanism of action of piracetam-like nootropics
11. Do piracetam-like compounds act centrally via peripheral mechanisms?
12. Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics
13. Arousal deficit shown in aged rat's quantitative EEG and ameliorative action of pramiracetam compared to piracetam
14. Pharmacologic therapeutic window of pramiracetam demonstrated in behavior, EEG, and single neuron firing rates
15. The effects of various cognition-enhancing drugs on in vitro rat hippocampal synaptosomal sodium dependent high affinity choline uptake
16. Reversal of scopolamine-induced alterations of choline transport across the blood-brain barrier by the nootropics piracetam and pramiracetam
17. Amnesia produced by intracerebroventricular injections of hemicholinium-3 in mice was prevented by pretreatment with piracetam-like compounds
18. A new one-trial test for neurobiological studies of memory in rats. II: Effects of piracetam and pramiracetam
19. Kynurenic acid and 5,7-dichlorokynurenic acids improve social and object recognition in male rats
20. Memory training and drug therapy act differently on memory and metamemory functioning: evidence from a pilot study
21. Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia
22. Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers
23. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam
24. Systemic administration of pramiracetam increases nitric oxide synthase activity in the cerebral cortex of the rat

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!